Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Global Blood rapeutics

These 10 Non-Covid Biotech Stocks Are Up 40% Or More This Year

Biotech stocks are scorching right now. But the best of the best have strong gains. Those include 10 with at least 40% growth this year.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022

Stock Market Gains On Tax, Climate, Health Care Bill; 6 Breakouts Amid Mixed Week Of Earnings

Stock Market Gains On Tax, Climate, Health Care Bill; 6 Breakouts Amid Mixed Week Of Earnings

The stock market gained on tax, climate health care bill. The latest week or earnings arrived with lackluster results.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022

Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion

Rumors that Pfizer is in "advanced talks" to acquire Global Blood Therapeutics for about $5 billion sent GBT stock flying Friday.

Investors Business Daily

12 Health Care Stocks Moving In Thursday's Intraday Session

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

inkl

Read news from The Economist, FT, and more,
with one subscription

Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91

Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91

A Relative Strength Rating upgrade for Global Blood Therapeutic shows improving technical performance.

Investors Business Daily

Looking Into Global Blood Therapeutics's Return On Capital Employed

Looking Into Global Blood Therapeutics's Return On Capital Employed

According to Benzinga Pro data, during Q1, Global Blood Therapeutics (NASDAQ:GBT) posted sales of $55.16 million. Earnings were up 7.03%, but Global Blood Therapeutics still reported an overall loss of $81.42 million.

Sickle cell: Just half of nurses and doctors feel confident about treating illness, report finds

Sickle cell: Just half of nurses and doctors feel confident about treating illness, report finds

Exclusive: The experiences of more than 1,300 people people living with the illness, carers and healthcare professionals, were examined

The Independent UK

Global Blood Therapeutics Earnings Perspective: Return On Capital Employed

Global Blood Therapeutics Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q1, Global Blood Therapeutics's (NASDAQ:GBT) reported sales totaled $55.16 million. Despite a 7.03% increase in earnings, the company posted a loss of $81.42 million.

Recap: Global Blood Therapeutics Q1 Earnings

Recap: Global Blood Therapeutics Q1 Earnings

Global Blood Therapeutics (NASDAQ:GBT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Looking Into Global Blood Therapeutics's Return On Capital Employed

Looking Into Global Blood Therapeutics's Return On Capital Employed

Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $56.10 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 23.37%, resulting in a loss of $87.58 million.

Organisations

European Commission

Food and Drug Administration

Western Digital

Investor Business Daily

Palantir Technologies

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Sickle Cell Disease

Ulcerative Colitis

Macular Degeneration

Amyotrophic lateral sclerosis

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

255,923 stories

107,992 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play